Navigation Links
ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
Date:2/20/2008

HALIFAX, Feb. 20 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, announced today the appointment of former senator, Michael Kirby, as the new Board of Directors Chair. Michael Kirby succeeds the late Dr. Warrick Kimmins, who provided exemplary leadership during his tenure and was instrumental in spinning out IVT's novel technology from Dalhousie University.

"I am passionate about advancing health care and am delighted to be part of such a fast-growing biotech company," said former senator Michael Kirby. "IVT has an impressive track record and its patented technology holds tremendous potential to improve vaccines worldwide. "

"Michael Kirby is an internationally respected leader in health care," said Dr. Randal Chase, IVT President and CEO. "His strategic advice will be invaluable, as we enter the next phase of development with the expectation of beginning a new Phase 1 clinical trial in 2009."

The Honourable Michael Kirby has had a distinguished career spanning academia, business, provincial, and federal public service. Most recently, he was appointed, by Prime Minister Stephen Harper, to be the first Chair of the Mental Health Commission of Canada. He also serves on several boards including The Bank of Nova Scotia, Extendicare, Ontario Energy Savings Income Trust, MDC Partners, and Indigo Books and Music.

Senator Kirby was past chair of the Standing Senate Committee on Social Affairs, Science and Technology. He has been a member of the Trilateral Commission, the Council of the International Institute for Applied Systems Analysis, Luxemburg, Austria, and the Club of Rome. He was also a full-time professor in the School of Business Administration and the School of Public Administration at Dalhousie University.

About IVT

ImmunoVaccine Technologies Inc. is a private, clinical-stage, vaccine development company. Through its own biotech research and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world.

The company, using its proprietary VacciMax(R) platform, is able to stimulate an earlier, more powerful, long lasting immune response that could provide a new way to treat cancer and infectious diseases.

In December 2007, IVT signed a binding MOU to acquire Pennsylvania-based Immunotope Inc. The acquisition enables IVT to create an entire pipeline of proprietary therapeutic cancer and infectious-disease specific vaccines. In January 2008, IVT licensed its technology to Pfizer Animal health, marking a pivotal step in achieving its vision of delivering breakthrough vaccines.

http://www.immunovaccine.com


'/>"/>
SOURCE ImmunoVaccine Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
2. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
3. NASA MidSTAR-1 successful technologies may be revolutionary
4. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
5. Neurobiological Technologies Sets Date for Research and Development Day
6. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
7. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
8. Emisphere Technologies to Web Cast BIO CEO & Investor Conference Presentation February 12
9. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
10. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
11. Genelabs Technologies to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Miami, FL (PRWEB) , ... February 10, 2016 ... ... leader in regenerative medicine, has announced a new agreement with Singapore-based Global Stem ... qualified physicians from the Philippines, Thailand and Singapore in the latest adipose and ...
(Date:2/9/2016)... LITTLE FALLS, N.J. , Feb. 9, 2016 ... ), a biotechnology company specializing in the development ... the health of damaged tissues and organs, recently ... milestones for the first quarter of 2016. ... Regenicin began the new 2015 fiscal year in ...
(Date:2/9/2016)... Prussia, PA (PRWEB) , ... February 09, 2016 , ... ... Development, Europe. Based in Paris, he will focus on acquiring new accounts and ... being met. , “Fred brings to our European clients more than ...
(Date:2/9/2016)... 9, 2016  DNAtrix, a clinical stage, ... announced that its lead product, DNX-2401, has ... an orphan medicinal product for the treatment ... glioma, strikes approximately 25,000 people a year ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
Breaking Biology Technology:
(Date:1/15/2016)... JUAN, Puerto Rico , Jan. 15, 2016 /PRNewswire/ ... companies big and small to find new ways to ... driven culture. iOS and Android ... device based on biometrics, transforming it into a hardware ... request that users swipe their fingerprint on their KodeKey ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
(Date:1/8/2016)... -- NXTD ), a company focused on ... privately held leading direct seller of vacation and entertainment ... company announced that on December 31, 2015, that WorldVentures ... to develop a proprietary new wireless smart card for ... unique smart wallet that serves to securely store all ...
Breaking Biology News(10 mins):